reason report
continu transit old new product
bottom line yesterday close report decent
beat consensu revenu yoy vs
consensu vs estim ep yoy vs
consensu vs estim double-digit growth
sever recent launch product off-set continu
declin compani larg legaci product ep beat
result combin typic season low expens
benefit us tax reform activ share repurchas base
quarter result increas revenu forecast
higher non-product revenu increas ep
estim base chang chang peer
compani multipl adjust price target amgen
maintain market perform rate
lack meaning near-term catalyst growth outlook
excit believ pressur legaci product
go increas hand disciplin
margin perform continu strong cash flow
well posit activ particip busi develop
opportun immin launch pdufa date may
aimovig compani cgrp receptor antibodi migrain
prevent captur investor attent expect
limit financi impact immedi futur manag
seem maintain cautiou stanc toward
opportun suggest valuat becom
attract compani continu evad question
potenti role larg scale consolid nevertheless sell sider
buy sider alik continu ponder perenni question
buy
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu million dilut non-gaap ep
pleas refer page import disclosur price chart analyst certif
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
unlik match legaci brand least mani year manag
respond challeng restructur compani expens base initi dividend
lever compani balanc sheet cash trap off-shore gener make
legaci product compar peer regard defens stock
also one lack explos upsid potenti typic associ breakthrough
beat consensu top bottom line total product sale grew y/i modestli
beat consensu estim beat primarili contribut
neulasta sensipar xgeva off-set weak franchis aranesp enbrel
kyproli repres largest miss enbrel report largest consensu miss
y/i declin q/q declin declin driven primarili lower unit
demand lesser extent lower net sell price favor prior year chang
account estim off-set partial favor chang inventori brand
materi surpris vs consensu sensipar beat
oper expens consensu ep expens
sequenti annual lower consensu
expect rel reduct oper expens continu compani
earlier restructur oper effici increas sg driven
pre-launch prepar aimovig biosimilar product sg like ramp strongli
futur quarter year expens declin y/i lower consensu
also like increas year cost sale margin
higher consensu expect togeth effect push oper margin
slightli lower quarter decreas y/i still
compani long-term guidanc despit higher expens benefit lower
share count us tax reform tax rate compar consensu
result report pro forma ep
estim consensu ep growth y/i driven one-off tax
benefit share repurchas rather top-lin growth expect market
reward stock much respons
revenu guidanc consensu tax reform boost ep rang manag
updat guidanc revenu midpoint
annual declin current consensu revenu
guidanc assum rang potenti sensipar gener competit outcom well new
potenti competit neulasta aranesp revis previou guidanc
oper margin manag expect oper margin lower
rest year previou year given time expens amgen tax rate
guidanc updat compar recent consensu
help boost non-gaap ep guidanc rang previou
guidanc rang bracket recent consensu near high end
also confirm intent invest annual capit expenditur
report free cash flow expect free cash flow rest year
lower due normal expens level payment repatri tax
share repurchas conduct plan deploy anoth
share buy-back consist previous announc plan share
repurchas year
without deal activ amgn pipelin lack catalyst continu maintain
one least excit late-stag pipelin larg cap biotech current intern
program far phase dramat alter trajectori without in-licens
acquisit activ pivot trial radar phase studi
infliximab biosimilar rheumatoid arthriti meaning catalyst includ regulatori
approv aimovig us potenti even eu label expans prolia
glucocorticoid-induc osteoporosi us timelin aimovig announc
previous pdufa date may compani provid detail us re-
submiss even continu scour entir clinic databas
experi even includ re-evalu case report studi valid
verifi cardiovascular cv event trial develop regulatori submiss
compani spent consider portion confer call highlight early-stag asset
interest includ bcma solid tumor bite car-t mutein
autoimmun diseas howev asset earli develop still lack compel proof
concept face often long uncertain path market
modest revenu expens chang lower pt market perform base
result quarter commentari manag maintain
revenu forecast increas revenu forecast futur year revenu
increas kyproli vectibix decreas significantli
sensipar updat revenu forecast
recent consensu consensu forecast
decreas ebit margin increas overal oper expens futur year
pro forma dilut ep estim decreas increas
due chang pro forma ep estim
consensu result chang
chang peer compani multipl updat price target previous
reiter market perform rate stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock azn sni
rhhbi gsk nv celg price sale multipl larg cap biotechnolog
pharma compani novo celg discount cash flow dcf use rel
multipl larg cap biopharma compani ep appli
ep estim give one year futur valu use establish larg
cap futur revenu multipl sale appli revenu forecast
give futur valu final dcf valuat base
current outlook compani exist product probability-weight revenu
contribut late stage pipelin program discount compani
wacc give fair valu today averag three approach give price
target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
